SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Schering AG And Biogen Idec, Inc. (Massachusetts) Announce Start Of The ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin